Lecanemab

Amyloid Beta-directed Antibody — NERVOUS SYSTEM

Key facts

Lecanemab is a drug in the Amyloid Beta-directed Antibody class catalogued in DrugCentral. It was first approved by the FDA in 2023. Its mechanism of action is classified as Amyloid Beta-directed Antibody Interactions. DrugCentral lists 1 molecular target, including APP. Recorded indications include Alzheimer's disease.

• Drug class: Amyloid Beta-directed Antibody.
• Mechanism of action: Amyloid Beta-directed Antibody Interactions.
• Molecular targets: APP (1 listed in DrugCentral).
• Indications: Alzheimer's disease.
• ATC code: N06DX04 (Other anti-dementia drugs).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Alzheimer's disease

Mechanism & targets

• Mechanism of action (MoA): Amyloid Beta-directed Antibody Interactions
• Established pharmacologic class: Amyloid Beta-directed Antibody

Molecular targets (1)

Target	Gene	Action	Activity
Amyloid beta A4 protein	APP	other	IC50 6.22

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2023-01-06	FDA	—	EISAI INC

ATC classification

ATC code	Therapeutic hierarchy
N06DX04	NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTI-DEMENTIA DRUGS › Other anti-dementia drugs

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label
• FDA label: APOE · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Amyloid related imaging abnormality-oedema/effusion	3245.3
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits	2937.8
Amyloid related imaging abnormalities	694.8
Infusion related reaction	499.6
Superficial siderosis of central nervous system	304.9
Headache	243.9
Cerebral haemorrhage	235.8
Chills	208.8
Cerebral infarction	187.6
Cerebral microhaemorrhage	123.2
Confusional state	91.4
Subdural haematoma	60.2

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: 1260393-98-3
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Lecanemab used for?

DrugCentral lists the following indications for Lecanemab: Alzheimer's disease.

How does Lecanemab work?

Lecanemab is classified as Amyloid Beta-directed Antibody Interactions; its molecular targets in DrugCentral include APP.

When was Lecanemab first approved?

Lecanemab was first approved by the FDA in 2023.

What drug class does Lecanemab belong to?

Lecanemab is in the Amyloid Beta-directed Antibody class.

Sources

• DrugCentral drug card 5717 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3833321 — compound record and bioactivity
• DrugBank DB14580 — drug record
• FDA UNII 12PYH0FTU9 — substance identity
• DailyMed: FDA labels for Lecanemab — current prescribing information (label search)
• UniProt P05067 (APP) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.